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Abstract
Background: The first line treatment against cutaneous leishmaniasis is meglumine antimoniate. This drug is expensive and has
serious side effects, including development of drug resistance.
Objectives: In this research, because of paucity of information, the apoptotic and leishmanicidal effects of ketotifen and cromolyn
sodium, as cell membrane stabilizer drugs, were investigated on standard strains of Leishmania major.
Methods: In this experimental study, L. major parasites were first cultured in RPM1 1640 media, supplemented with 10% fetal bovine
serum (FBS) and antibiotics at 24 ± 1ºC. Drug concentrations of 5, 10, 15, and 20 µg/mL were then added to L. major culture at 24-,
48- and 72-hour intervals. The 3 - (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide (MTT) tetrazolium assays were per-
formed to determine parasite viability and drug toxicity. Leishmania major promastigotes were augmented to the in vitro cultured
macrophages (J774 cells) and then incubated for 72 hours. Half maximal inhibitory concentration (IC50) were ascertained by count-
ing the parasites. The inhibitory effect of the drugs were compared with that of glucantime. Flow-cytometry was performed in the
next step, to evaluate apoptosis. Each test was repeated three times.
Results: IC50 values of ketotifen and cromolyn sodium at 20 µg/mL concentrations after 72 hours were calculated to be 2.04 and
17.67µg/mL for promastigotes and 0.12 and 14.79µg/mL for amastigotes, respectively. The results of MTT assays showed a 20% and 35%
decrease in promastigote viability after 72 hours of exposure to ketotifen and cromolyn sodium at 20 µg/mL concentration. Apop-
tosis in ketotifen and cromolyn sodium was quantified to be 11.52% and 9.96% in promastigotes and 99.5% and 98.6% in amastigote-
infected macrophages, respectively. The results indicated that the drugs induce early and late apoptosis in parasites. All treatments
produced results, which differed significantly from the control groups (P < 0.05).
Conclusions: Drugs used in this study, especially Ketotifen, showed lower toxicity yet similar anti-leishmanial effects on both forms,
as cromolyn sodium did. It could be suggested that further investigations about the in vivo effects of these drugs, as candidates for
cutaneous leishmaniasis treatment, are required.
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1. Background
Leishmaniasis is one of major parasitic diseases, which
causes various health complications for human popula-
tions particularly in endemic regions. The agent respon-
sible for this disease is a protozoan parasite of the Try-
panosomatidae family and Leishmania genus. The devel-
opment of disease depends on many factors, such as the
parasite species, inoculum size, and route of transmission,
host immunity, and genetic attributes (1-3). Two pentava-
lent antimonials, such as glucantime (meglumine anti-
moniate) and pentostam (sodium stibogluconate), are the
first line treatment against cutaneous leishmaniasis (4, 5).
These drugs have many common side effects, which ob-
scure their therapeutic successes. These include toxicity,
drug resistance, refractory wounds, relapse of illness, and
more recently, Leishmania-HIV coinfection. Hence, treating
the disease is necessary, particularly when humans are the
main host (6).
Many studies have examined medical herbs, nanopar-
ticles, and other chemotherapeutic agents to treat leish-
maniasis. Cromolyn sodium and ketotifen inhibit pene-
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tration of parasites to cells by stabilizing cell membrane.
H1 antagonist drugs inhibit mastocyte secretion and re-
lease of histamine, chemokine, and other vasoactive sub-
stances, known to be involved in asthma and allergic rhini-
tis. These drugs have also shown anti-stress effects, besides
their common anti-allergic properties (7).
Ketotifen, a tricyclic antihistaminic drug (Zaditen®),
is prescribed widely as tablets or syrups for treatment
of allergic disorders, such as allergic conjunctivitis,
chronic rhinitis, urticaria, and asthma. Cromolyn sodium
(Allergocrom® and Intal®), prescribed as inhalant cap-
sules, nasal inhalers, and eye drops, is one of the highly
consumed and effective antihistamines in the treatment
of respiratory sensitivities caused by allergens. Cromolyn
sodium inhibits histamine and leukotriene release as well
as activation of inflammatory cells, such as eosinophils.
However, there is no comprehensive study yet to deter-
mine the effectivity of these drugs in the treatment of
cutaneous leishmaniasis (8, 9).
2. Objectives
The current study therefore aimed at investigating cy-
totoxic damage and programmed apoptosis induced by




This study was approved by the Ethics Committee of
Iran University of Medical Sciences, in accordance with
the Helsinki Declaration guidelines with approval Code
No:IR.IUMS.REC.FMD. 96-01-30-30371.
3.2. Preparation of Drugs
The pure powders of ketotifen (C19H19NOS) with a
molecular weight of 309.426 g/mol and cromolyn sodium
(C23H14Na2O11 ) with a molecular weight of 512.334 g/mol
were obtained from Sigma-Aldrich. The stock solutions
of ketotifen were prepared with distilled water to make
a consecrated solution of 250 µg/mL. Desired concentra-
tions were prepared by dilution. glucantime was also pur-
chased from Sigma, and used as a standard control drug.
The solutions of glucantime were prepared as mentioned
above.
3.3. Parasite Culture
For this study, the Iranian standard strain of Leishma-
nia (MRHO/IR/75/ER) was obtained from Tehran University
of Medical Sciences. Batch production of Leishmania para-
sites was carried out in RPMI 1640 media, which was pur-
chased from Gibco©. As supplementary, 10% Fetal Bovine
Serum (FBS) was added to the media as well as 100 unit/mL
penicillin and 100 mg/mL streptomycin, to inhibit bacte-
rial growth. The culture was then kept under 18 to 24ºC in
an incubator and examined daily under an invert micro-
scope. Cell passage was carried out every 72 hours and each
test was done in triplicates.
3.4. Promastigote Growth Inhibition Assay
In order to calculate IC50 of the tested drugs on L. ma-
jor promastigotes, similar aliquots of promastigotes, con-
taining 106 cell milliliters were added to various concentra-
tion (5, 10, 15, 20µg/mL) of ketotifen and cromolyn sodium
drugs at 24, 48, and 72 hours. The temperature was main-
tained at 18°C to 24°C and test plates were examined under
the microscope on a daily basis. One well, containing only
promastigote and medium, was designated as the nega-
tive control, whereas another containing glucantime with
concentration 20 µg/mL and medium in addition to pro-
mastigotes was designated as the positive control. Finally,
IC50 was obtained by plotting the applied doses against
time intervals to produce a dose-response curve and calcu-
late the corresponding linear regression (10).
3.5. The MTT Assay of Anti-Leishmanial Activity of Drugs Against
Promastigotes
The colorimetric method of 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide tetrazolium (MTT) as-
say was used to evaluate anti-leishmanial activity of tested
drugs. To this end, aliquots containing 106 logarithmic
phase promastigotes, were added to different doses of
drugs, prepared in 96-well plates under completely ster-
ile conditions. Wells on the edges were filled with PBS to
reduce evaporation. The plates were incubated for 24, 48
and 72 hours at 18°C to 24°C. Wells containing medium in
each plate were assigned as the negative control, while oth-
ers containing medium and glucantime were assigned as
the positive control. After incubation, plates were taken
out, centrifuged, and supernatants were decanted before
adding the MTT solution. Plates were again incubated for
four hours under the same temperature. This allowed an
adequate time for the MTT yellow solution to permeate to
parasite cells to produce purple formazan crystals by re-
acting with succinate dehydrogenase, available in kineto-
plasts. To dissolve formazan crystals, dimethyl sulfoxide
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(DMSO) was then added to the wells and stirred in dark-
ness on a shaker for 10 to 15 minutes. Absorption ratio was
read at the 490 nm wavelength, using an enzyme linked
immunosorbent assay (ELISA) reader. Given that the num-
ber of viable cells correlates with optical density (OD) at the
absorbed wavelength, percentages of viable cells in con-
trol and test wells were calculated using the corresponding
formula (10).
3.6. MTT Assay to Evaluate Drug Toxicity on Macrophages
Balb/c peritoneal macrophages (J774A.1 cell line), pro-
vided by the Faculty of Health of Tehran University, were
cultured at 105 per well in plates, before adding drug con-
centrations. The wells on edges were filled with PBS to pre-
vent evaporation in wells containing cells. The MTT solu-
tion was added to wells after an incubation period of 24,
48, and 72 hours, followed by incubation for four more
hours at 18°C to 24°C. Supernatants were then decanted
and DMSO was added to all wells. The absorption was read
at 490 nm wavelength, using an ELISA reader. To deter-
mine relative absorption (SI: stimulation index), the opti-
cal density of each sample was calibrated against the back-
ground of absorption in the control well (medium plus
macrophage).
3.7. Amastigote Growth Inhibition Assay
Promastigotes in static phase (106 cells) in addition
to macrophages and different doses of ketotifen and cro-
molyn sodium (5, 10, 15, and 20 µg/mL) were added to an
eight-well chamber slide. One chamber was filled only
with macrophages acting as the negative control and an-
other was filled with medium and glucantime, with con-
centration of 20 µg/mL, acting as the positive control
chamber. The plates were then incubated for 24, 48, and 72
hours at 35°C. The parasites that were not introduced to the
macrophage, were entered from the environment by wash-
ing with PBS. The prepared smears were then fixed with
methanol and stained with Giemsa. Amastigote count in
100 macrophages was done by averaging the number of
amastigotes in each macrophage. To obtain the average
number of amastigotes in each macrophage, the obtained
number was divided by one hundred.
3.8. Cell Death Assessment Using Flow-Cytometry
Annexin V and propidium iodide (PI) staining were ap-
plied to differentiate between necrotic and apoptotic pro-
mastigotes and amastigotes-infected macrophages, which
had been exposed to various doses of ketotifen and cro-
molyn sodium. For this purpose, cells exposed to various
drug doses as well as control cells exposed to PBS were cen-
trifuged for 10 minutes at 1400 g force and then washed.
According to the kit manual, 100 µL of Annexin-V solution
and PI solution was then added to sedimented cells. Sus-
pension was incubated for 15 minutes at room tempera-
ture in a dark place. Color intensity of absorbed Annexin-
V by the cells was measured using the FACSCaliber device
and results were analyzed with the Cell Quest software (11,
12).
3.9. Statistical Analysis
One-way Analysis of Variances (One-way ANOVA) to
compare the mean of parasite count in each drug and also
in its related concentrations and t-test for detecting signifi-
cant differences between control and test groups were per-
formed to analyze the results using the SPSS software ver-
sion 20. The difference was considered significant at P <
0.05.
4. Results
4.1. Assessment of Drug Efficacy Using the Parasite Count
After 24, 48, and 72 hours of incubation in the presence
of different doses of ketotifen parasite, it was shown that
the number of promastigotes was reduced to significant
levels compared with the control group (P < 0.05). The
IC50 of ketotifen after 72 hours was calculated to be 2.04
µg/mL. IC50 of cromolyn sodium was estimated to be 17.67
µg/mL after 72 hours of exposure. Parasite counts (mean±
SD) upon exposure to 20 µg/mL concentration of glucan-
time at the same time intervals post-exposure were 0.7 ±
0.05, 0.58±0.07, and 0.47±0.03, and in the control group
were 2.15 ± 0.02, 2.25 ± 0.03, and 2.29 ± 0.03 respectively.
There were not any significant differences between differ-
ent concentrations of drugs (P > 0.05). (Tables 1 and 2).
Table 1. Number (Mean ± SD) of Promastigotes After Adding Ketotifena
Ketotifen, µg/mL
Promastigote (106)
24 h 48 h 72 h
5 1.35 ± 0.01 1.14 ± 0.02 1.10 ± 0.02
10 1.25 ± 0.01 0.99 ± 0.02 0.80 ± 0.02
15 1.24 ± 0.03 1.06 ± 0.04 0.77 ± 0.01
20 1.21 ± 0.03 1.01 ± 0.03 0.71 ± 0.02
a P < 0.05.
4.2. Results of MTT Assays for Viable Cells Assessment
The promastigotes exposed to the highest concentra-
tion of ketotifen (20µg/mL) during 72 hours of incubation
showed 20% survival. This result was significantly differ-
ent from the control test (P < 0.05). Cells incubated with
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Table 2. Number (Mean ± SD) of Promastigotes After Adding Cromolyn Sodiuma
Cromolyn Sodium, µg/mL
Promastigote (106)
24 h 48 h 72 h
5 1.82 ± 0.02 1.61 ± 0.03 1.40 ± 0.02
10 1.80 ± 0.03 1.68 ± 0.01 1.32 ± 0.04
15 1.76 ± 0.03 1.57 ± 0.02 1.28 ± 0.02
20 1.56 ± 0.02 1.36 ± 0.02 1.02 ± 0.03












Figure 1. Percentage of live promastigotes after adding different concentrations of
ketotifen and glucantime during the incubation times (P value for each concentra-
tion of the drugs: P > 001)
cromolyn sodium at the same concentration and for the
same exposure time showed only 35% viability, which also
differed significantly from the control (P < 0.05) (Figures 1
and 2). There were not any significant differences between
different concentrations of drugs (P > 0.05).
4.3. Results of MTT Assays for Toxicity Assessment
Toxicity of different doses of drugs were assessed on
macrophage cells. Results showed higher toxicity than cro-
molyn sodium (53%) compared to ketotifen (17%). All the
results were statistically significant compared to the con-
trols (P < 0.05). These results were the average of at least
three separate experiments.
4.4. Number of Amastigotes Inside Macrophage Cells
The results acquired from numeration of intracellu-
lar amastigotes showed that drugs reduced the viability
of amastigotes in J774.A1 macrophages at a concentration
and dose-dependent mode. Differences between test and
control groups were significant (P < 0.05). IC50 of keto-
tifen after 72 hours of exposure was calculated to be 0.12
µg/mL while IC50 of cromolyn sodium for the same expo-
sure time was 14.79 µg/mL (Figures 3 and 4). There were
not any significant differences between different concen-












Figure 2. Percentage of live promastigotes after adding different concentrations
of cromolyn sodium and glucantime during the incubation times (P value for each












Figure 3. Percentage of amastigotes inside macrophage cells after increasing differ-
ent concentrations of ketotifen during the incubation times (P value for each con-












Figure 4. Percentage of amastigotes inside macrophage cells after increasing dif-
ferent concentrations of cromolyn sodium during the incubation times. (P value
for each concentration of the drugs: P > 001)
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4.5. Results of Flow-Cytometry
The programmed cell death of Leishmania promastig-
ote cultured in control media, for 72 hours was 0.823%,
while that of amastigotes-infected macrophages was
30.75% after 72 hours of culture. The apoptosis rates of
promastigotes treated with ketotifen at different con-
centrations including 5, 10, 15 and 20 µg/mL were 2.23%,
5.24%, 9.61% and 11.52%, respectively while these rates were
98.4%, 99.1%, 99.3%, and 99.5% for amastigotes-infected
macrophages, treated with the same doses of the same
drug.
In promastigotes treated with 5, 10, 15 and 20 µg/mL
of cromolyn sodium, the apoptosis rates were 1.61%, 4.68%,
5.31%, and 9.96%, respectively. The apoptosis rates of
amastigotes -infected macrophages were 96.9%, 98.6%,
98.7%, and 98.6% after 72 hours of exposure (Figures 5 and
6). All the results of both promastigotes and amastigotes-
infected macrophages were significantly different com-
pared to the controls (P < 0.05).
5. Discussion
As mentioned previously, drug resistance has been a
major obstacle for Leishmania treatment, hence, develop-
ing inexpensive, accessible and orally applicable drugs
with low side effects is essential, especially when humans
are involved as reservoirs. There is an immediate require-
ment for guides on new inventive drugs (12-14). Hermoso
et al. investigated anti-leishmanial effects of Piper elon-
gatum extract against promastigotes. They showed a log-
ical description for the use of this extract (15). Using
flow-cytometry, Ghaffarifar et al. studied the effect of
artemisinin on L. major growth and their mechanism of ac-
tion relating to programmed cell death. The authors ob-
served that higher parasite death rates occur when drug
doses were increased. The aforementioned study reported
that the highest cell death occurred at 100 µg/mL concen-
tration and the lowest cell death occurred at 10 µg/mL (11).
Doroodgar et al. showed that tamoxifen-induced apopto-
sis was dose-dependent as well. Ebrahimisadr et al. re-
ported that artemether had an apoptotic effect on Leishma-
nia major promastigotes and could prevent the growth of
both Leishmania In vitro (12, 16). Maroufi et al. reported that
cantharidin at different concentrations and times induced
apoptosis in L. major promastigotes and macrophages in-
fected with amastigotes (17).
Pinto et al. studied the effect of a series of histamine
H1-receptor antagonists on promastigotes and amastig-
otes of L. infantum. They reported the IC50 value for ke-
totifen to be 13 µmol, which is comparable to the values
obtained by the current study, although the Leishmania
strains differed from each other in both studies. This work
described, for the first time, the activity of H1-antagonists
versus L. infantum and their possible efficiency in a specu-
lative mice model. The evaluation showed that these drugs
exert leishmanicidal effects against promastigotes. These
researchers postulated that the drugs were the first anti-
histaminic drugs with anti-leishmanial activities and sug-
gested that the drugs could be used as a platform for drug
model studies for visceral leishmaniasis.
The anti-infective activity of H1-antagonist derivatives
has also been explained versus Mycobacterium tuberculosis.
These drugs have also been described as a calcium chan-
nel blocker. Anti-leishmanial and anti-trypanosomal activ-
ities of calcium channel blockers have been demonstrated
(18). Rezaei et al. studied the effect of ketotifen and cro-
molyn sodium at different drug doses within 30 to 60 min-
utes of exposure time on stabilization of cell membrane
in order to prevent penetration of Toxoplasma gondii into
Balb/c cells. Their results indicated that ketotifen and cro-
molyn sodium prevent entry of tachyzoites to nucleated
cells, both In vitro and In vivo (7).
Ibrahim et al. showed that ketotifen was effective
on Plasmodium falciparum both as a stand-alone drug or
in combination with malaria common drugs (9). You et
al. reported that P. yoelii parasites may be successfully
treated with a combination of low dose of ketotifen and
chloroquine. This causes the parasites to sometimes die
faster with sporadic membranes and vacuoles damages
(19). Daryani et al. reported that ketotifen was more effec-
tive in preventing penetration of Toxoplasma tachyzoites to
macrophages at 10 µg/mL concentration after 60 minutes
of exposure. They assumed that T. gondii microtubules also
act on each other with dinitroaniline. The cytoskeleton ev-
idently executes significant functions in movement, intru-
sion, and endodyogeny. Interruption of any of these essen-
tial functions might be adopted to kill or disable the para-
site.
The researchers have reported that cytochalasin D pre-
vented the entry of T. gondii to peritoneal macrophages and
bladder tumor cells following a joint dosage yet did not
avert connection. Microfilaments are incriminated to be
a frequent place of activity in delaying entry of T. gondii
to cells. The researchers have showed that dinitroaniline
herbicides avert T. gondii replication. Trifluralin also binds
Leishmania tubulin and averts polymerization of subpel-
licular microtubules. In Plasmodium, Trifluralins restrains
fragments of the subpellicular microtubules of gameto-
cytes, also delaying erythrocytic stages and exflagellation
of gametocytes (7, 20). Montazeri et al. showed that both
ketotifen and pyrimethamine had prophylactic and cura-
tive results on acute phases of the disease. The combined
treatment with ketotifen and pyrimethamine strongly pre-
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Figure 5. Flow cytometry analysis of promastigotes following treatment with various concentrations of ketotifen for 72 hours and after labeling with annexin-V and PI. Lower
and upper right regions (LR) belong to early and late apoptotic cells (annexin positive) and upper left region (UL) belong to necrotic cells (PI positive)
vents T. gondiiin vivo (21). The used drugs in the current
study stabilize cell membrane and prevent parasite entry
to the host cells. This research found that drug efficacy was
dose and exposure time dependent so that by increasing
exposure time and drug concentration, the parasite count
decreased.
The MTT assay results showed that upon exposure to
high doses of ketotifen and cromolyn sodium, percentage
of viable promastigotes decreased when enough time was
allowed. Under the said conditions, the viability of pro-
mastigotes was significantly different from that of the con-
trol group (P < 0.05). The drugs were significantly different
from the control in terms of toxic effect (P < 0.05). Drugs
used in this study, especially ketotifen, showed lower toxi-
city yet the same anti-Leishmania effects on both forms as
cromolyn sodium did. These drugs were also able to in-
duce apoptosis in promastigotes and amastigotes-infected
macrophages of L. major, significantly different from the
control groups (P < 0.05). The results showed that drugs
used in this study were less effective on induction of
programmed cell death in promastigotes, while they ex-
erted greater effect on apoptosis of amastigotes-infected
macrophages.
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Figure 6. Flow cytometry analysis of amastigotes, following treatment with various concentrations of cromolyn sodium for 72 hours and after labeling with annexin-V and
PI. Lower and upper right regions (LR) belong to early and late apoptotic cells (annexin positive) and upper left region (UL) belong to necrotic cells (PI positive)
5.1. Conclusions
In this research, because of paucity of information,
the apoptotic and leishmanicidal effects of ketotifen and
cromolyn sodium were investigated on standard strains
of L. major. The primary objective was to investigate the
potency of the drugs and report on optimal doses, if
proved effective. In contrast to cromolyn sodium, keto-
tifen showed higher inhibitory effects on both forms of the
parasite, and lower toxicities to uninfected macrophages.
ketotifen also showed stronger apoptosis induction of
programmed cell death on amastigote and promastigote
forms of the parasite. Therefore, further In vivo studies are
suggested to evaluate the application of different doses of
ketotifen for the treatment of leishmaniasis.
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